Association of vaccine policy with virus infection and awareness of hepatitis B in Fujian, China

References

• Zhao H, Zhou X, Zhou YH. Hepatitis B vaccine development and implementation. Hum Vaccin Immunother. 2020;16(7):1533–8. doi:10.1080/21645515.2020.1732166.
   PubMed Web of Science ®Google Scholar
• Krugman S. The newly licensed hepatitis B vaccine. Characteristics and indications for use. JAMA. 1982;247(14):2012–15. doi:10.1001/jama.1982.03320390074052.
   PubMed Web of Science ®Google Scholar
• Lu FM, Zhuang H. Management of hepatitis B in China. Chin Med J. 2009;122:3–4. doi:10.1111/j.1365-2893.2010.01266.x.
   PubMed Web of Science ®Google Scholar
• Wu JN, Zhou Y, Zhang DJ, Zheng JF, Pan WY, Cai ZK, Yan YS. Study on the authenticity of immunization coverage of the routine immunization coverage surveillance system of Fujian. Chin J Epidemiol. 2011;32(9):946–48.
   Google Scholar
• Zhang M, Zheng JS, Cao L. Performance and methods of quality assessment of routine immunization coverage surveillance. Chin J Vaccin Immun. 2015;21:450–57.
   Google Scholar
• Hutton DW, So SK, Brandeau ML. Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China. Hepatology. 2010;51(2):405–14. doi:10.1002/hep.23310.
   PubMed Web of Science ®Google Scholar
• Tang J, Luo YQ, Zhou YH. Elimination of hepatitis B virus infection in children: experience and challenge in China. Chin Med J. 2021;134(23):2818–24. doi:10.1097/CM9.0000000000001791.
   PubMed Web of Science ®Google Scholar
• Wu JN, Wen XZ, Zhou Y, Lin D, Zhang SY, Yan YS. Impact of the free-vaccine policy on timely initiation and completion of hepatitis B vaccination in Fujian, China. J Viral Hepat. 2015;22(6):551–60. doi:10.1111/jvh.12359.
   PubMed Web of Science ®Google Scholar
• Huang L, Zhou Y, Yang X. Epidemiological characteristics of hepatitis B infection in 1-29 year old population in Fujian Province. Strait J Pre Med. 2018;24:32–33.
   Google Scholar
• Wang H, Men P, Xiao Y, Gao P, Lv M, Yuan Q, Chen W, Bai S, Wu J. Hepatitis B infection in the general population of China: a systematic review and meta-analysis. BMC Infect Dis. 2019;19(1):811. doi:10.1186/s12879-019-4428-y.
   PubMed Web of Science ®Google Scholar
• Liang XF, Bi SL, Yang WZ, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, et al. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27(47):6550–57. doi:10.1016/j.vaccine.2009.08.048.
   PubMed Web of Science ®Google Scholar
• Wu JN, Li DJ, Zhou Y. Association between timely initiation of hepatitis B vaccine and completion of the hepatitis B vaccine and national immunization program vaccine series. Int J Infect Dis. 2016;51:62–65. doi:10.1016/j.ijid.2016.08.018.
   PubMed Web of Science ®Google Scholar
• Cui F, Shen L, Li L, Wang H, Wang F, Bi S, Liu J, Zhang G, Wang F, Zheng H, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerg Infect Dis. 2017;23(5):765–72. doi:10.3201/eid2305.161477.
   PubMed Web of Science ®Google Scholar
• Fujian Provincial Health Commission, Fujian Center for Disease Control and Prevention. 40th anniversary of immunization program in Fujian province. Fujian Science and Technology Press;2019 Sept.
   Google Scholar
• Rothman KJ, Greenland S. Modern epidemiology. Philadelphia: Lippincott-Raven; 1998.
   Google Scholar
• Liao X, Liang Z. Strategy vaccination against hepatitis B in China. Hum Vaccin Immunother. 2015;11(6):1534–39. doi:10.4161/21645515.2014.980206.
   PubMed Web of Science ®Google Scholar
• McMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, Bulkow L, Fiore A, Bell B, Hennessy T. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis. 2009;200(9):1390–96. doi:10.1086/606119.
   PubMed Web of Science ®Google Scholar
• Wu JN, Huang LF, Lin ZQ, Zhou Y. Association between vaccine dose and risk of hepatitis B virus infection in Fujian Province, China. Hum Vaccin Immunother. 2022;18(7):2153533. doi:10.1080/21645515.2022.2153533.
   PubMedGoogle Scholar
• Wu JN, Zhou Y. Factors associated with and screening models of national immunization program completion for preschool children in Fujian, China. J Infect Public Health. 2019;12(2):236–41. doi:10.1016/j.jiph.2018.10.011.
   PubMed Web of Science ®Google Scholar
• Wu JN, Li DJ, Zhou Y, Du MR, Piao HL. Relationship between receipt of substitutable for free vaccines and completion of the expanded program on immunization: a cross-sectional study in Fujian, China. BMJ Open. 2017;7(7):e015666. doi:10.1136/bmjopen-2016-015666.
   PubMed Web of Science ®Google Scholar
• Wu J, Zhou Y, Huang L, He A. Study on the effects of timely initiation and completion of hepatitis B vaccine on hepatitis B virus prevention in Fujian, China. China J Epidemiol. 2014;35(4):471–72.
   Google Scholar
• Huang C, Zeng S, Chen X. Epidemiological characteristics of immunoprophylaxis failure in the infants born to HBsAg positive mothers in Quanzhou, Fujian. J China Trop Med. 2020;20:245–58.
   Google Scholar
• Bierhoff M, Angkurawaranon C, Rijken M, Sriprawa K, Kobphan P, Nosten FN, van Vugt M, McGready R, Devine A. Tenofovir disoproxil fumarate in pregnancy for prevention of mother to child transmission of hepatitis B in a rural setting on the Thailand-Myanmar border: a cost-effectiveness analysis. BMC Pregnancy Childbirth. 2021;21(1):157. doi:10.1186/s12884-021-03612-z.
   PubMed Web of Science ®Google Scholar
• Kyuregyan KK, Kichatova VS, Isaeva O, Potemkin IA, Malinnikova EY, Lopatukhina MA, Karlsen AA, Asadi Mobarhan FA, Mullin EV, Slukinova OS, et al. Coverage with timely administered vaccination against hepatitis B virus and its influence on the prevalence of HBV infection in the regions of different endemicity. Vaccines. 2021;9(2):82. doi:10.3390/vaccines9020082.
   Web of Science ®Google Scholar
• National Health and Family Planning Commission of China. Notice on the issuance of China’s viral hepatitis prevention and control program (2017–2020). No.53; 2017.
   Google Scholar
• Gürakar M, Malik M, Keskin O, Idilman R. Public awareness of hepatitis B infection in Turkey as a model of universal effectiveness in health care policy. Turk J Gastroenterol. 2014;25(3):304–08. doi:10.5152/tjg.2014.6718.
   PubMed Web of Science ®Google Scholar
• Ganczak M, Dmytrzyk-Danilow G, Korzen M, Drozd-Dąbrowska M, Szych Z. Prevalence of HBV infection and knowledge of hepatitis B among patients attending primary care clinics in Poland. J Commun Health. 2016;41(3):635–44. doi:10.1007/s10900-015-0139-5.
   PubMed Web of Science ®Google Scholar
• Nwokediuko SC. Chronic hepatitis B: management challenges in resource-poor countries. Hepat Mon. 2011;11(10):786–93. doi:10.5812/kowsar.1735143X.3519.
   PubMed Web of Science ®Google Scholar
• Liang Y, Bai X, Liu X, Zhang Z, Pang X, Nie L, Qiu W, Zhao W, Hu G. Hepatitis B vaccination coverage rates and associated factors: a community-based, cross-sectional study conducted in Beijing, 2019–2020. Vaccines. 2021;9(10):1070. doi:10.3390/vaccines9101070.
   Web of Science ®Google Scholar
• Cohen C, Evans AA, Huang P, London WT, Block JM, Chen G. Hepatitis B knowledge among key stakeholders in Haimen City, China: implications for addressing chronic HBV infection. Hepatol Med Policy. 2016;1(1):4. doi:10.1186/s41124-016-0004-x.
   PubMedGoogle Scholar
• Tan SHS, Wang D, Tan WJ, Allameen NA, Fong NP. Facilitators and barriers of hepatitis B screening and vaccination. Vaccine. 2020;38(34):5447–53. doi:10.1016/j.vaccine.2020.06.045.
   PubMed Web of Science ®Google Scholar